Gough Ryan, Treffy Randall W, Krucoff Max O, Desai Rupen
Department of Neurosurgery, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Cancers (Basel). 2025 Jan 2;17(1):124. doi: 10.3390/cancers17010124.
Glioblastoma is the most common primary brain tumor in adult patients, and despite standard-of-care treatment, median survival has remained less than two years. Advances in our understanding of molecular mutations have led to changes in the diagnostic criteria of glioblastoma, with the WHO classification integrating important mutations into the grading system in 2021. We sought to review the basics of the important genetic mutations associated with glioblastoma, including known mechanisms and roles in disease pathogenesis/treatment. We also examined new advances in image processing as well as less invasive and noninvasive diagnostic tools that can aid in the diagnosis and surveillance of those undergoing treatment for glioblastoma. Our review is intended to serve as an overview of the current state-of-the-art in the diagnosis and management of glioblastoma.
胶质母细胞瘤是成年患者中最常见的原发性脑肿瘤,尽管采用了标准治疗方案,但中位生存期仍不足两年。我们对分子突变的理解取得了进展,这导致了胶质母细胞瘤诊断标准的改变,世界卫生组织(WHO)分类于2021年将重要突变纳入分级系统。我们试图回顾与胶质母细胞瘤相关的重要基因突变的基础知识,包括已知的机制及其在疾病发病机制/治疗中的作用。我们还研究了图像处理方面的新进展以及侵入性较小和非侵入性的诊断工具,这些工具有助于胶质母细胞瘤患者的诊断和治疗监测。我们的综述旨在概述胶质母细胞瘤诊断和管理的当前最新技术水平。